Ventyx Biosciences Stock Alpha and Beta Analysis
| VTYX Stock | USD 1.41 0.02 1.44% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Ventyx Biosciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Ventyx Biosciences over a specified time horizon. Remember, high Ventyx Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Ventyx Biosciences' market risk premium analysis include:
Beta 1.55 | Alpha (0.53) | Risk 4.71 | Sharpe Ratio (0.14) | Expected Return (0.67) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Ventyx |
Ventyx Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Ventyx Biosciences market risk premium is the additional return an investor will receive from holding Ventyx Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Ventyx Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Ventyx Biosciences' performance over market.| α | -0.53 | β | 1.55 |
Ventyx Biosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Ventyx Biosciences' Buy-and-hold return. Our buy-and-hold chart shows how Ventyx Biosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Ventyx Biosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Ventyx Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Ventyx Biosciences shares will generate the highest return on investment. By understating and applying Ventyx Biosciences stock market price indicators, traders can identify Ventyx Biosciences position entry and exit signals to maximize returns.
Ventyx Biosciences Return and Market Media
The median price of Ventyx Biosciences for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 2.01 with a coefficient of variation of 20.39. The daily time series for the period is distributed with a sample standard deviation of 0.41, arithmetic mean of 1.99, and mean deviation of 0.34. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 116668 shares by Raju Mohan of Ventyx Biosciences subject to Rule 16b-3 | 12/17/2024 |
2 | Acquisition by Gujrathi Sheila of 130000 shares of Ventyx Biosciences at 2.3121 subject to Rule 16b-3 | 12/23/2024 |
3 | Disposition of 21119 shares by John Nuss of Ventyx Biosciences at 2.36 subject to Rule 16b-3 | 12/27/2024 |
4 | Insider Sell John Nuss Sells 21,119 Shares of Ventyx Biosciences Inc | 12/31/2024 |
5 | Acquisition by Forman Mark S of 85000 shares of Ventyx Biosciences at 2.14 subject to Rule 16b-3 | 01/02/2025 |
6 | Acquisition by Gonzales Roy of 17500 shares of Ventyx Biosciences at 2.14 subject to Rule 16b-3 | 01/03/2025 |
7 | Were Keeping An Eye On Ventyx Biosciences Cash Burn Rate | 01/10/2025 |
8 | HC Wainwright Analysts Increase Earnings Estimates for VTYX - MarketBeat | 01/17/2025 |
9 | Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference | 02/05/2025 |
10 | Acquisition by John Nuss of 7972 shares of Ventyx Biosciences at 3.54 subject to Rule 16b-3 | 02/13/2025 |
11 | Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohns Disease at ECCO 2025 | 02/18/2025 |
12 | Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights ... | 02/27/2025 |
13 | Class Action Filed Against Ventyx Biosciences, Inc. - April 30, 2024 Deadline to Join - Contact Levi Korsinsky - ACCESS Newswire | 03/03/2025 |
14 | Acquisition by Gujrathi Sheila of 33000 shares of Ventyx Biosciences at 3.285 subject to Rule 16b-3 | 03/05/2025 |
15 | Disposition of 4531 shares by John Nuss of Ventyx Biosciences subject to Rule 16b-3 | 03/07/2025 |
16 | Disposition of 1735306 shares by Subramaniam Somu of Ventyx Biosciences subject to Rule 16b-3 | 03/10/2025 |
17 | Disposition of tradable shares by Gonzales Roy of Ventyx Biosciences subject to Rule 16b-3 | 03/11/2025 |
18 | Acquisition by Matthew Moore of 320000 shares of Ventyx Biosciences at 4.98 subject to Rule 16b-3 | 03/12/2025 |
About Ventyx Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Ventyx or other stocks. Alpha measures the amount that position in Ventyx Biosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 (projected) | Current Ratio | 20.21 | 11.87 | 17.97 | Net Debt To EBITDA | 0.59 | 0.19 | 0.11 |
Ventyx Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Ventyx Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ventyx Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Ventyx Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Ventyx Biosciences. Please utilize our Beneish M Score to check the likelihood of Ventyx Biosciences' management manipulating its earnings.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Ventyx Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Ventyx Stock Analysis
When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.